Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2023 May 4

PMID 37138422

Authors

Daljeet Singh Dhanjal

Reena Singh

Varun Sharma

Eugenie Nepovimova

Vojtech Adam

Kamil Kuca

Chirag Chopra

Affiliations

Soon will be listed here.

Abstract

The foundations of cell reprogramming were laid by Yamanaka and co-workers, who showed that somatic cells can be reprogrammed into pluripotent cells (induced pluripotency). Since this discovery, the field of regenerative medicine has seen advancements. For example, because they can differentiate into multiple cell types, pluripotent stem cells are considered vital components in regenerative medicine aimed at the functional restoration of damaged tissue. Despite years of research, both replacement and restoration of failed organs/ tissues have remained elusive scientific feats. However, with the inception of cell engineering and nuclear reprogramming, useful solutions have been identified to counter the need for compatible and sustainable organs. By combining the science underlying genetic engineering and nuclear reprogramming with regenerative medicine, scientists have engineered cells to make gene and stem cell therapies applicable and effective. These approaches have enabled the targeting of various pathways to reprogramme cells, i.e., make them behave in beneficial ways in a patient-specific manner. Technological advancements have clearly supported the concept and realization of regenerative medicine. Genetic engineering is used for tissue engineering and nuclear reprogramming and has led to advances in regenerative medicine. Targeted therapies and replacement of traumatized , damaged, or aged organs can be realized through genetic engineering. Furthermore, the success of these therapies has been validated through thousands of clinical trials. Scientists are currently evaluating induced tissue-specific stem cells (iTSCs), which may lead to tumour-free applications of pluripotency induction. In this review, we present state-of-the-art genetic engineering that has been used in regenerative medicine. We also focus on ways that genetic engineering and nuclear reprogramming have transformed regenerative medicine and have become unique therapeutic niches.

References

Ryall J, Cliff T, Dalton S, Sartorelli V . Metabolic Reprogramming of Stem Cell Epigenetics. Cell Stem Cell. 2015; 17(6):651-662. PMC: 4672395. DOI: 10.1016/j.stem.2015.11.012. View

Mall M, Wernig M . The novel tool of cell reprogramming for applications in molecular medicine. J Mol Med (Berl). 2017; 95(7):695-703. PMC: 5487694. DOI: 10.1007/s00109-017-1550-4. View

Spemann H, Mangold H . Induction of embryonic primordia by implantation of organizers from a different species. 1923. Int J Dev Biol. 2001; 45(1):13-38. View

Hemmi J, Mishra A, Hornsby P . Overcoming barriers to reprogramming and differentiation in nonhuman primate induced pluripotent stem cells. Primate Biol. 2020; 4(2):153-162. PMC: 7041531. DOI: 10.5194/pb-4-153-2017. View

Nizzardo M, Simone C, Falcone M, Riboldi G, Comi G, Bresolin N . Direct reprogramming of adult somatic cells into other lineages: past evidence and future perspectives. Cell Transplant. 2012; 22(6):921-44. DOI: 10.3727/096368912X657477. View

Ilic D, Polak J . Stem cells in regenerative medicine: introduction. Br Med Bull. 2011; 98:117-26. DOI: 10.1093/bmb/ldr012. View

Ullah I, Subbarao R, Rho G . Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015; 35(2). PMC: 4413017. DOI: 10.1042/BSR20150025. View

Sisakhtnezhad S, Matin M . Transdifferentiation: a cell and molecular reprogramming process. Cell Tissue Res. 2012; 348(3):379-96. DOI: 10.1007/s00441-012-1403-y. View

Le Magnen C, Shen M, Abate-Shen C . Lineage Plasticity in Cancer Progression and Treatment. Annu Rev Cancer Biol. 2018; 2:271-289. PMC: 5942183. DOI: 10.1146/annurev-cancerbio-030617-050224. View

10.

Nakagawa H, Whelan K, Lynch J . Mechanisms of Barrett's oesophagus: intestinal differentiation, stem cells, and tissue models. Best Pract Res Clin Gastroenterol. 2015; 29(1):3-16. PMC: 4352719. DOI: 10.1016/j.bpg.2014.11.001. View

11.

Ye L, Robertson M, Mastracci T, Anderson R . An insulin signaling feedback loop regulates pancreas progenitor cell differentiation during islet development and regeneration. Dev Biol. 2015; 409(2):354-69. PMC: 4950988. DOI: 10.1016/j.ydbio.2015.12.003. View

12.

Yamamizu K, Piao Y, Sharov A, Zsiros V, Yu H, Nakazawa K . Identification of transcription factors for lineage-specific ESC differentiation. Stem Cell Reports. 2013; 1(6):545-59. PMC: 3871400. DOI: 10.1016/j.stemcr.2013.10.006. View

13.

Palomo A, Lucas M, Dilley R, McLenachan S, Chen F, Requena J . The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation. J Clin Med. 2015; 3(2):373-87. PMC: 4449681. DOI: 10.3390/jcm3020373. View

14.

Bhartiya D, Hinduja I, Patel H, Bhilawadikar R . Making gametes from pluripotent stem cells--a promising role for very small embryonic-like stem cells. Reprod Biol Endocrinol. 2014; 12:114. PMC: 4255929. DOI: 10.1186/1477-7827-12-114. View

15.

Son M, Lee M, Jeon H, Seol B, Kim J, Chang J . Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. Exp Mol Med. 2016; 48:e232. PMC: 4910148. DOI: 10.1038/emm.2016.27. View

16.

Li M, Cascino P, Ummarino S, Di Ruscio A . Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases. Cells. 2017; 6(1). PMC: 5371872. DOI: 10.3390/cells6010007. View

17.

Halley-Stott R, Pasque V, Gurdon J . Nuclear reprogramming. Development. 2013; 140(12):2468-71. DOI: 10.1242/dev.092049. View

18.

Tahmasebi S, Jafarnejad S, Tam I, Gonatopoulos-Pournatzis T, Matta-Camacho E, Tsukumo Y . Control of embryonic stem cell self-renewal and differentiation via coordinated alternative splicing and translation of YY2. Proc Natl Acad Sci U S A. 2016; 113(44):12360-12367. PMC: 5098618. DOI: 10.1073/pnas.1615540113. View

19.

Singh V, Saini A, Kalsan M, Kumar N, Chandra R . Describing the Stem Cell Potency: The Various Methods of Functional Assessment and Diagnostics. Front Cell Dev Biol. 2016; 4:134. PMC: 5118841. DOI: 10.3389/fcell.2016.00134. View

20.

Xiao J, Yang R, Biswas S, Qin X, Zhang M, Deng W . Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis. Int J Mol Sci. 2015; 16(5):9283-302. PMC: 4463588. DOI: 10.3390/ijms16059283. View